Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease
Taisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunky...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-02-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/profile-of-daprodustat-in-the-treatment-of-renal-anemia-due-to-chronic-peer-reviewed-article-TCRM |
| _version_ | 1818684071156383744 |
|---|---|
| author | Ishii T Tanaka T Nangaku M |
| author_facet | Ishii T Tanaka T Nangaku M |
| author_sort | Ishii T |
| collection | DOAJ |
| description | Taisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 1138655, JapanTel +81-3-3815-5411Fax +81-3-5800-9826Email mnangaku-tky@umin.ac.jpAbstract: Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.Keywords: prolyl hydroxylase domain, hypoxia-inducible factor, erythropoietin, iron |
| first_indexed | 2024-12-17T10:44:48Z |
| format | Article |
| id | doaj.art-f7bc19af972b4ef4b01564c2effb0336 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-12-17T10:44:48Z |
| publishDate | 2021-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-f7bc19af972b4ef4b01564c2effb03362022-12-21T21:52:10ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2021-02-01Volume 1715516362236Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney DiseaseIshii TTanaka TNangaku MTaisuke Ishii, Tetsuhiro Tanaka, Masaomi Nangaku Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, JapanCorrespondence: Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 1138655, JapanTel +81-3-3815-5411Fax +81-3-5800-9826Email mnangaku-tky@umin.ac.jpAbstract: Anemia is a major complication of chronic kidney disease (CKD), which mainly results from appropriate erythropoietin production impairment. Prolyl hydroxylase domain (PHD) inhibitors are currently being developed and approved in some countries as a new treatment for CKD patients with anemia due to the stabilization of intracellular hypoxia-inducible factor (HIF) 1α and HIF2α by PHD inhibition. Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients. In addition, some international Phase 3 studies are underway to confirm these effects and reveal the safety profile. This article summarizes the development process and results of each clinical trial.Keywords: prolyl hydroxylase domain, hypoxia-inducible factor, erythropoietin, ironhttps://www.dovepress.com/profile-of-daprodustat-in-the-treatment-of-renal-anemia-due-to-chronic-peer-reviewed-article-TCRMprolyl hydroxylase domainhypoxia inducible factorerythropoietiniron |
| spellingShingle | Ishii T Tanaka T Nangaku M Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease Therapeutics and Clinical Risk Management prolyl hydroxylase domain hypoxia inducible factor erythropoietin iron |
| title | Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease |
| title_full | Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease |
| title_fullStr | Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease |
| title_full_unstemmed | Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease |
| title_short | Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease |
| title_sort | profile of daprodustat in the treatment of renal anemia due to chronic kidney disease |
| topic | prolyl hydroxylase domain hypoxia inducible factor erythropoietin iron |
| url | https://www.dovepress.com/profile-of-daprodustat-in-the-treatment-of-renal-anemia-due-to-chronic-peer-reviewed-article-TCRM |
| work_keys_str_mv | AT ishiit profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease AT tanakat profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease AT nangakum profileofdaprodustatinthetreatmentofrenalanemiaduetochronickidneydisease |